EA200801732A1 - Модуляторы ауроракиназы, способы их получения и их применение - Google Patents

Модуляторы ауроракиназы, способы их получения и их применение

Info

Publication number
EA200801732A1
EA200801732A1 EA200801732A EA200801732A EA200801732A1 EA 200801732 A1 EA200801732 A1 EA 200801732A1 EA 200801732 A EA200801732 A EA 200801732A EA 200801732 A EA200801732 A EA 200801732A EA 200801732 A1 EA200801732 A1 EA 200801732A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aurorakinase
methods
compounds
activity
modulators
Prior art date
Application number
EA200801732A
Other languages
English (en)
Other versions
EA018128B1 (ru
Inventor
Виктор Дж. Сии
Холли Л. Дик
Бингфэн Ду
Стефани Д. Геунс-Мейер
Брайан Л. Ходоус
Ханх Нхо Нгуйен
Филип Р. Оливиери
Винод Ф. Пател
Карина Ромеро
Лори Шенкел
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/655,642 external-priority patent/US7560551B2/en
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA200801732A1 publication Critical patent/EA200801732A1/ru
Publication of EA018128B1 publication Critical patent/EA018128B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)

Abstract

Настоящее изобретение относится к химическим соединениям, имеющим общую формулу, где A, A, С, С, L, L, Z и Rопределены в описании, и к синтетическим промежуточным продуктам, которые способны модулировать различные ферменты, рецепторы протеинкиназ и тем самым влиять на различные болезненные состояния и условия, связанные с активностью таких киназ. Например, соединения способны модулировать ауроракиназы, влияя при этом на процесс клеточного цикла и пролиферацию клеток с целью лечения рака и болезней, связанных с раком. Изобретение также предусматривает фармацевтические композиции, включающие указанные соединения, и способы лечения болезненных состояний, связанных с активностью ауроракиназы.
EA200801732A 2006-01-23 2007-01-22 Модуляторы аурора киназы, способы их получения и их применение EA018128B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76167506P 2006-01-23 2006-01-23
US11/655,642 US7560551B2 (en) 2006-01-23 2007-01-18 Aurora kinase modulators and method of use
PCT/US2007/001714 WO2007087276A1 (en) 2006-01-23 2007-01-22 Aurora kinase modulators and method of use

Publications (2)

Publication Number Publication Date
EA200801732A1 true EA200801732A1 (ru) 2009-02-27
EA018128B1 EA018128B1 (ru) 2013-05-30

Family

ID=40849087

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801732A EA018128B1 (ru) 2006-01-23 2007-01-22 Модуляторы аурора киназы, способы их получения и их применение

Country Status (21)

Country Link
EP (1) EP1984353B1 (ru)
JP (2) JP5280862B2 (ru)
KR (2) KR101300424B1 (ru)
AU (2) AU2007208351C1 (ru)
BR (1) BRPI0706684A2 (ru)
CA (1) CA2637658C (ru)
CR (1) CR10213A (ru)
DK (1) DK1984353T3 (ru)
EA (1) EA018128B1 (ru)
ES (1) ES2502790T3 (ru)
GE (1) GEP20125643B (ru)
HK (1) HK1167140A1 (ru)
HR (1) HRP20160039T1 (ru)
HU (1) HUE028504T2 (ru)
IL (1) IL192812A (ru)
MA (1) MA30224B1 (ru)
MY (1) MY161884A (ru)
NO (1) NO20083639L (ru)
NZ (1) NZ569815A (ru)
TN (1) TNSN08310A1 (ru)
WO (1) WO2007087276A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101300424B1 (ko) * 2006-01-23 2013-08-26 암젠 인크 오로라 키나제 조절제 및 사용 방법
WO2008124083A2 (en) * 2007-04-05 2008-10-16 Amgen Inc. Aurora kinase modulators and method of use
ES2413806T3 (es) 2008-03-20 2013-07-17 Amgen Inc. Moduladores de la aurora cinasa y método de uso
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
ES2433469T3 (es) * 2008-08-04 2013-12-11 Amgen Inc. Moduladores de la aurora cinasa y métodos de uso
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
MX2011006575A (es) 2008-12-17 2011-10-06 Amgen Inc Compuestos de aminopiridina y carboxipiridina como inhibidores de la fosfodiesterasa 10.
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP2012529535A (ja) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
AU2010292225C1 (en) 2009-09-11 2013-06-27 Amgen Inc. N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
MX369738B (es) 2013-12-03 2019-11-20 Amgen Inc Formas cristalinas de sales de n-(4-((3-(2-amino-4-pirimidinil)-2- piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas.
EA034912B1 (ru) 2015-06-03 2020-04-06 Бристол-Маерс Сквибб Компани 4-гидрокси-3-(гетероарил)пиридин-2-оновые агонисты apj для применения в лечении сердечно-сосудистых заболеваний
US10647675B2 (en) 2015-09-18 2020-05-12 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
JP7032903B2 (ja) * 2016-10-12 2022-03-09 田辺三菱製薬株式会社 スルホンアミド化合物の製造方法
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN111302948A (zh) * 2020-04-13 2020-06-19 长兴进源新材料科技有限公司 一种2,2-双(4-氨基苯基)六氟丙烷合成方法
WO2024167848A1 (en) * 2023-02-06 2024-08-15 Type6 Therapeutics, Inc. Compounds, compositions, and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770600B2 (en) * 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
NZ522696A (en) 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
US6864255B2 (en) * 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
BRPI0215312B8 (pt) 2001-12-24 2021-05-25 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
FR2853378B1 (fr) 2003-04-02 2006-03-10 Carbone Lorraine Composants Plaquettes de frein a disque ventilees
CA2553160C (en) * 2003-12-29 2010-09-28 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
EP1751136B1 (en) * 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
KR101300424B1 (ko) * 2006-01-23 2013-08-26 암젠 인크 오로라 키나제 조절제 및 사용 방법

Also Published As

Publication number Publication date
WO2007087276A1 (en) 2007-08-02
JP5280862B2 (ja) 2013-09-04
AU2007208351C1 (en) 2011-07-07
AU2010241280B2 (en) 2013-02-28
AU2007208351A1 (en) 2007-08-02
CA2637658A1 (en) 2007-08-02
JP2009528268A (ja) 2009-08-06
AU2010241280A1 (en) 2010-11-25
AU2007208351B2 (en) 2010-08-05
TNSN08310A1 (en) 2009-12-29
MA30224B1 (fr) 2009-02-02
MY161884A (en) 2017-05-15
KR20080095889A (ko) 2008-10-29
HUE028504T2 (en) 2016-12-28
EP1984353B1 (en) 2015-12-30
NZ569815A (en) 2011-11-25
CR10213A (es) 2008-10-03
GEP20125643B (en) 2012-09-25
IL192812A (en) 2014-06-30
IL192812A0 (en) 2009-02-11
NO20083639L (no) 2008-10-22
JP5753546B2 (ja) 2015-07-22
KR101332975B1 (ko) 2013-11-25
HK1167140A1 (en) 2012-11-23
KR20110133056A (ko) 2011-12-09
CA2637658C (en) 2012-07-17
ES2502790T3 (es) 2014-10-06
KR101300424B1 (ko) 2013-08-26
HRP20160039T1 (hr) 2016-02-12
JP2013136585A (ja) 2013-07-11
EP1984353A1 (en) 2008-10-29
DK1984353T3 (en) 2016-03-14
BRPI0706684A2 (pt) 2011-04-05
EA018128B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
EA200801732A1 (ru) Модуляторы ауроракиназы, способы их получения и их применение
MX2009010517A (es) Moduladores de cinasa aurora y metodos de uso.
JOP20210154B1 (ar) مثبطات kif18a
MX2021007104A (es) Inhibidores de kif18a.
MX2021007157A (es) Heteroarilamidas utiles como inhibidores de kif18a.
MX2021007158A (es) Heteroarilamidas utiles como inhibidores de kif18a.
MX2022001181A (es) Inhibidores de kif18a.
MX2022001302A (es) Inhibidores de kif18a.
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
ATE478861T1 (de) Multizyklische verbindung und verwendungsverfahren
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA200970738A1 (ru) Ингибиторы активности akt
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA200870048A1 (ru) ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
EA200971013A1 (ru) Соединения-антагонисты рнк для модуляции активности бета-катенина
EA200800014A1 (ru) Аминохинолиновые и аминохиназолиновые модуляторы киназы
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
UA98297C2 (en) Triazolopyridazines as tyrosine kinase modulators
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA201100604A1 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
EA201400707A1 (ru) Дизамещенные бензотиенил-пирролотриазины и их применение в качестве ингибиторов киназы рфрф

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM